Device type · QWZ
Prognostic Test For Assessment Of Chronic Kidney Disease Progression
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
QWZ
Clinical Chemistry
Device class
Class II
FDA decisions since 2015
1
510(k), De Novo and PMA
Adverse event reports
0
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Prognostic Test For Assessment Of Chronic Kidney Disease Progression
- Product code
- QWZ
- Device class
- Class II
- Review panel
- Clinical Chemistry
- Regulation
- 21 CFR 862.1223
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for QWZ
Latest FDA decisions
- KidneyIntelX.dkdNew device typeBreakthroughDe Novo
DEN200052 · Decided Jun 29, 2023 · 1,037 days after receipt
Device type: Prognostic Test For Assessment Of Chronic Kidney Disease Progression (QWZ) · Laboratory Medicine & Pathology
Reports received
0
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
No reports to chart for this view.
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
No manufacturers to rank.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
No device problems coded.
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
No patient problems coded.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Kidney TestOpen, Classified
Z-0800-2026 · Started Nov 3, 2025 · Posted by FDA Dec 1, 2025
Reason given: Distribution without premarket approval/clearance.
Cause as FDA categorized it: No Marketing Application
- Liver TestOpen, Classified
Z-0801-2026 · Started Nov 3, 2025 · Posted by FDA Dec 1, 2025
Reason given: Distribution without premarket approval/clearance.
Cause as FDA categorized it: No Marketing Application
- Allergy & Food Intolerance TestOpen, Classified
Z-0802-2026 · Started Nov 3, 2025 · Posted by FDA Dec 1, 2025
Reason given: Distribution without premarket approval/clearance.
Cause as FDA categorized it: No Marketing Application
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.